Detalhe da pesquisa
1.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Ann Rheum Dis
; 82(7): 901-910, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36931693
2.
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Dig Dis Sci
; 68(6): 2624-2634, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739367
3.
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Clin Gastroenterol Hepatol
; 20(3): 591-601.e8, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684552
4.
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
Gut
; 70(2): 418-426, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32699100
5.
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States.
Clin Gastroenterol Hepatol
; 19(10): 2210-2213.e3, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34089848
6.
Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
J Clin Gastroenterol
; 54(10): 911, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32740101
7.
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
J Crohns Colitis
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700040
8.
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
J Crohns Colitis
; 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38877972
9.
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
J Crohns Colitis
; 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38613425
10.
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Adv Ther
; 40(10): 4440-4459, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37525075
11.
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts.
Inflamm Bowel Dis
; 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934789
12.
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Inflamm Bowel Dis
; 29(1): 85-96, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35648151
13.
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
J Crohns Colitis
; 17(11): 1761-1770, 2023 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37402275
14.
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
J Crohns Colitis
; 17(3): 338-351, 2023 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124702
15.
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
J Crohns Colitis
; 17(7): 1066-1078, 2023 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738443
16.
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Clin Pharmacol Ther
; 112(1): 90-100, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380740
17.
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
Aliment Pharmacol Ther
; 55(3): 302-310, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626429
18.
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program.
Therap Adv Gastroenterol
; 15: 17562848221136331, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36506749
19.
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Aliment Pharmacol Ther
; 55(4): 464-478, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34854095
20.
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
J Med Econ
; 24(1): 279-290, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502905